CLDX Celldex Therapeutics

Celldex Therapeutics to Present at Cantor Global Healthcare Conference

Celldex Therapeutics to Present at Cantor Global Healthcare Conference

HAMPTON, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Cantor Global Healthcare Conference on Tuesday, September 26th at 1:00 pm ET. A webcast of the presentation will be available on the "" page of the "" section of the Celldex website. A replay will be available for 90 days following the event.

About Celldex Therapeutics, Inc.

Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit .

Company Contact

Sarah Cavanaugh

Senior Vice President, Corporate Affairs & Administration

(508) 864-8337

Patrick Till

Meru Advisors

(484) 788-8560



EN
25/09/2023

Underlying

CLDXCelldex Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Celldex Therapeutics

 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Presents Additional Positive Data from Phase 2 Chronic Spontan...

Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026 - Sustained off-treatment efficacy despite barzolvolimab clearance and normalization of tryptase, suggesting disease modification in patients with CSU treated for full 52 weeks -- Greatly improved quality of life and reduced disease impact for patients with ColdU/SD at Week 20 -HAMPTON, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Celld...

11h / 3m 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Reports Fourth Quarter and Year End 2025 Financial Results and...

Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update Enrollment completed in both Phase 3 chronic spontaneous urticaria global registration studies (EMBARQ-CSU 1 and 2) six months ahead of guidance; Topline data expected in Q4 26; BLA submission planned for 2027Phase 3 cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) actively accruing Enrollment completed in Phase 2 prurigo nodularis and atopic dermatitis studies with topline data expected in 2026 Phase 1 CDX-622 Proof of Mechanism study in asthma initiatedCompany prepares...

February 25, 2026 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 an...

Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria Enrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSUTopline data expected Q4 2026BLA submission planned for 2027 HAMPTON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the completion of enrollment in the Company’s global Phase 3 program of barzolvolimab in chronic spontaneous urticaria (CSU), which consists of two Phase 3 trials—EMBARQ-CSU1 and EMBARQ-CSU2. 1,939 p...

February 25, 2026 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Suppor...

Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab’s First-in-Class and Best-in-Disease Profile HAMPTON, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that multiple presentations from the Company’s Phase 2 clinical trials of barzolvolimab in chronic spontaneous urticaria (CSU) and cold urticaria (ColdU) and symptomatic dermographism (SD) have been accepted for presentation at the 2026 American Academy of Allergy, Asthma & Immunology's (AAAAI) Annual Meeting being held in Philadelphia, February 27 – March 2. New data fr...

February 23, 2026 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex to Present at Upcoming Investor Conferences

Celldex to Present at Upcoming Investor Conferences HAMPTON, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at the following upcoming investor conferences: Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11 at 3:30 pm ETTD Cowen 46th Annual Health Care Conference on Wednesday, March 4 at 9:10 am ETLeerink Global Healthcare Conference on Tuesday, March 10 at 3:40 pm ET Live webcasts of the presentations will be available on the "" page of the "Investors" section of the Celldex websit...

February 9, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch